Non-Small Cell Lung Cancer Therapeutics Market: Snapshot

A research study, recently published by Transparency Market Research (TMR), estimates the global non-small cell lung cancer (NSCLC) therapeutics market to expand at a healthy CAGR of 12.10% over the period from 2015 to 2023 and reach a value of US$15.1 bn by the end of the forecast period.The report, titled “Non Small Cell Lung Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023,” states that the worldwide NSCLC market attained US$4.9 bn in 2014.

Browse the full Non Small Cell Lung Cancer Therapeutics Market: (By Drug Class: Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023 report at http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

Non-small cell lung cancer (NSCLC) has been identified as the most common type of epithelial lung cancer. Adenocarcinomas, squamous cell carcinomas, and large cell carcinomas are the major types of NSCLC. Unlike small cell lung cancer (SCLC), NSCLC exhibits low receptivity to chemotherapy, owing to which, the need for NSCLC therapeutics has been persistently escalating in the global arena.

In this research report, the global market for NSCLC therapeutics has been evaluated on the basis of the drug class, the pipeline stage, and the regional spread of this market. Based on the drug class, the market has been classified into angiogenesis inhibitor, kinase inhibitor, epidermal growth factor receptor blocker, microtubule stabilizer, PD-1/PD-L1 Inhibitor, and folate antimetabolites.

In 2014, angiogenesis inhibitor was the most demanded drug class in the global arena. The high efficiency of this drug class fueled its demand in the U.S., Japan, Europe, and other major regions.

Avastin and Cyramza are the two main angiogenesis inhibitors available in this market. Analysts expect this segment to expand at a CAGR of 1.80% during the forecast period and increase from a value of US$1.6 bn in 2014 to US$2 bn by the end of the forecast period.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Based on the pipeline stage, NSCLC therapeutics has been categorized into early-stage (phase 1 and phase 2) pipeline drugs and late-stage (phase 3) pipeline drugs. MEDI4736 (AstraZeneca), Avelumab (Pfizer Inc.), Abemaciclib (Eli Lilly and Co.), and MPDL3280A (Roche) are the major late-stage pipeline drugs.

Regionally, the study segments the global market for NSCLC therapeutics into Asia Pacific, Europe, North America, and the Rest of the World. North America led the overall market in 2014 and was closely followed by Asia Pacific. However, Asia Pacific is anticipated to register the fastest growth rate over the forecast period.

The presence of state-of-art healthcare infrastructure and existence of a favorable reimbursement scenario are the key factors that drove the North America NSCLC therapeutics market. Besides, the growing awareness about NSCLC and the increasing implementation of government initiative to curb lung cancer are likely to boost the Asia Pacific market for NSCLC therapeutics in the coming years, notes the study.

AstraZeneca Plc, GlaxoSmithKline Plc, Genentech Inc., Eli Lilly & Co., Boehringer Ingelheim, Pfizer Inc., Celgene Corp., Roche Holding AG, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the leading players in the global NSCLC therapeutics market, states the research report.

The global NSCLC market is segmented into:

By Drug Class

Angiogenesis Inhibitor
Avastin (bevacizumab)
Cyramza (Ramucirumab)
Epidermal Growth Factor Receptor Blocker
Tarceva (erlotinib)
Gilotrif (afatinib)
Iressa (gefitinib)
Kinase Inhibitor
Xalkori (crizotinib)
Zykadia (ceritinib)
Microtubule Stabilizer
Abraxane (paclitaxel protein bound)
Docetaxel
Folate Antimetabolites
Alimta (pemetrexed)
PD-1/ PD-L1 Inhibitor
Opdivo (nivolumab)
Keytruda (pembrolizumab)
By Pipeline

Early-Stage (Phase I and II)
Late-Stage (Phase III)
Avelumab Pfizer Inc.)
MPDL3280A (Roche)
MEDI4736 (AstraZeneca)
Abemaciclib (Eli Lilly and Co.)
Others

By Region

North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia Pacific
Japan
China
Rest of Asia Pacific
Rest of the World

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.